Scienture Holdings, Inc.

TRxADE HEALTH, INC. (the “ Company ”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “ Quarterly Report ”). The Company has determined that it is unable to file its Quarterly Report within the prescribed time period without unreasonable effort or expense because additional time is required to finalize its financial statements and related disclosures required to be included in the Quarterly Report. The Company is working diligently to complete the Quarterly Report as soon as possible and intends to file the Quarterly Report on or before the fifth calendar day following the prescribed due date

TRxADE HEALTH, INC. (the “ Company ”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the annual period ended December 31, 2023 (the “ Annual Report ”). The Company has determined that it is unable to file its Annual Report within the prescribed time period without unreasonable effort or expense because additional time is required to finalize its financial statements and related disclosures required to be included in the Annual Report. The Company is working diligently to complete the Annual Report as soon as possible and intends to file the Annual Report on or before the fifteenth calendar day following the prescribed due date

TRxADE HEALTH, Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 (the “Q3 2023 Form 10-Q”) by the prescribed due date because additional time is required to finalize its financial statements and related disclosures required to be included in the Q3 2023 Form 10-Q. The Company anticipates that it will file its Q3 2023 Form 10-Q within the five-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended. PART IV – OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification Suren Ajjarapu 800 261-0281 (Name) (Area Code) (Telephone Number) (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. See Annex A, attached. TRxADE HEALTH, Inc. (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 15, 2023 By: /s/ Suren Ajjarapu Chief Executive Officer Annex A

TRxADE HEALTH, Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the “Q2 2023 Form 10-Q”) by the prescribed due date because additional time is required to finalize its financial statements and related disclosures required to be included in the 10-Q in connection with the recent merger transaction it completed in July. The Company anticipates that it will file its Q2 2023 Form 10-Q within the five-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended